Skip to Content

Vanderbilt-Ingram Cancer CenterVanderbilt-Ingram Cancer Center


Learn More

VICC toll-free number 1-877-936-8422

Clinical Trial VICCGI13100


A Phase 2B, Randomized, Controlled, Multicenter, Open-Label Study of the Efficacy and Immune Response of GVAX Pancreas Vaccine (with Cyclophosphamide) and CRS-207 Compared to Chemotherapy or to CRS-207 Alone in Adults with Previously-Treated Metastatic Pancreatic Adenocarcinoma

Principal Investigator(s)

Emily Chan


  • Protocol No. VICCGI13100
  • Open Date: 06/10/2014
  • Staging: Phase II
  • Age Group: Adults
  • Scope: National
  • Objective: The primary objective of this study is to compare OS in the Primary Cohort between subjects receiving sequential administration of low-dose cyclophosphamide, GVAX pancreas vaccine and CRS-207 (Treatment Arm A) with subjects receiving chemotherapy (Treatment Arm C), where the Primary Cohort are subjects who have failed at least 2 prior treatment regimens (including at least one gemcitabine-based treatment) for metastatic disease (3rd+ line subjects).
  • Disease Sites: Pancreatic
  • Therapies: Chemotherapy - cytotoxic; Molecular Targeted Agents / Immunotherapy / Biologics; Vaccine
  • Drugs: 5-FU (Fluorouracil); CRS-207; Capecitabine; Cyclophosphamide (CTX); GVAX Pancreas Vaccine; Gemcitabine; Irinotecan (Camptosar, CPT-11); Tarceva (OSI-774; erlotinib)
  • Participating Institutions: Vanderbilt University
  • National Clinical Trial ID: NCT02004262
  • Secondary Protocol No: ADU-CL-04


None Provided.


Ages Eligible for Study:18 Years and older
Genders Eligible for Study:Both
Accepts Healthy Volunteers:No


Inclusion Criteria:
• Have histologically proven malignant adenocarcinoma of the pancreas; measurable disease is not required, mixed histology is not allowed; subjects must have metastatic disease
• 2nd line, 3rd line or greater
• At least 18 years of age
• ECOG of 0 or 1
• Anticipated life expectancy >12 weeks
• For women and men of childbearing potential, a medically acceptable method of highly effective contraception (oral hormonal contraceptive, condom plus spermicide, or hormone implants) must be used throughout the study period and for 28 days after their final vaccine administration. (A barrier method of contraception must be employed by all subjects [male and female], regardless of other methods.)
• Have adequate organ function as defined by specified laboratory values
Exclusion Criteria:
• Allergy to both penicillin & sulfa or suspected hypersensitivity to GM-CSF, dimethyl sulfoxide, fetal bovine serum, trypsin, yeast, glycerol or other component of the therapy options
• Known history or evidence of brain metastases, immunodeficiency disease or immunocompromised state or or history of autoimmune disease requiring systemic steroids or other immunosuppressive treatment
• Have any evidence of hepatic cirrhosis or clinical or radiographic ascites
• Have prosthetic heart valves, major implant or device placed in the last 12 months or history of infection with implant/device that cannot be easily removed
• Rapidly progressing disease
• Clinically significant and/or malignant pleural effusion
• Received prior GVAX pancreas vaccine or CRS-207
• Major surgery or significant traumatic injury (or unhealed surgical wounds) occurring within 28 days prior to receiving study drug, or planned surgery requiring general anesthesia
• Infection with HIV or hepatitis B or C at screening
• Valvular heart disease that requires antibiotic prophylaxis for prevention of endocarditis
• Be pregnant or breastfeeding
• Unable to avoid close contact with another individual known to be at high risk of listeriosis (e.g., newborn infant, pregnant woman, HIV-positive individual) during the course of CRS-207 treatment until completion of antibiotic regimen
• Conditions, including alcohol or drug dependence, intercurrent illness, or lack of sufficient peripheral venous access, that would affect the patient's ability to comply with study visits and procedures